

1 **SARS-CoV-2 viral load dynamics, duration of viral shedding and infectiousness – a living**  
2 **systematic review and meta-analysis**

3

4 **Author:** Muge Cevik<sup>1,2</sup>, Matthew Tate<sup>3</sup>, Ollie Lloyd<sup>2,4</sup>, Alberto Enrico Maraolo<sup>5</sup>, Jenna  
5 Schafers<sup>2</sup>, Antonia Ho<sup>6</sup>

6

7 **Affiliations:**

8 1. Division of Infection and Global Health Research, School of Medicine, University of St  
9 Andrews, UK

10 2. NHS Lothian Infection Service, Regional Infectious Diseases Unit, Western General  
11 Hospital, Edinburgh, U.K.

12 3. Respiratory Medicine, University Hospital Wishaw, Wishaw, UK

13 4. Edinburgh Medical School, College of Medicine & Veterinary Medicine, University of  
14 Edinburgh, UK

15 5. First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, Naples, Italy.

16 6. MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow,  
17 UK

18

19

20 **Corresponding author:**

21 Dr Muge Cevik

22 Division of Infection and Global Health Research,

23 School of Medicine, University of St Andrews, Fife, KY16 9TF

24 Telephone number: +447732800814

25 Email address: [mc349@st-andrews.ac.uk](mailto:mc349@st-andrews.ac.uk)

26

27 **Keywords:** SARS-CoV-2, COVID-19, viral shedding, viral dynamics, infectiousness

28 **ABSTRACT**

29 **Background** Viral load kinetics and the duration of viral shedding are important determinants for  
30 disease transmission. We aim i) to characterise viral load dynamics, duration of viral RNA, and  
31 viable virus shedding of SARS-CoV-2 in various body fluids and ii) to compare SARS-CoV-2 viral  
32 dynamics with SARS-CoV-1 and MERS-CoV.

33 **Methods:** Medline, EMBASE, Europe PMC, preprint servers and grey literature were searched  
34 to retrieve all articles reporting viral dynamics and duration of SARS-CoV-2, SARS-CoV-1 and  
35 MERS-CoV shedding. We excluded case reports and case series with < 5 patients, or studies  
36 that did not report shedding duration from symptom onset. PROSPERO registration:  
37 CRD42020181914.

38 **Findings:** Seventy-nine studies on SARS-CoV-2, 8 on SARS-CoV-1, and 11 on MERS-CoV were  
39 included. Mean SARS-CoV-2 RNA shedding duration in upper respiratory tract, lower respiratory  
40 tract, stool and serum were 17.0, 14.6, 17.2 and 16.6 days, respectively. Maximum duration of  
41 SARS-CoV-2 RNA shedding reported in URT, LRT, stool and serum was 83, 59, 35 and 60 days,  
42 respectively. Pooled mean duration of SARS-CoV-2 RNA shedding was positively associated with  
43 age ( $p=0.002$ ), but not gender ( $p = 0.277$ ). No study to date has detected live virus beyond day  
44 nine of illness despite persistently high viral loads. SARS-CoV-2 viral load in the upper respiratory  
45 tract appears to peak in the first week of illness, while SARS-CoV-1 and MERS-CoV peak later.

46 **Conclusion:** Although SARS-CoV-2 RNA shedding in respiratory and stool can be prolonged,  
47 duration of viable virus is relatively short-lived. Thus, detection of viral RNA cannot be used to infer  
48 infectiousness. High SARS-CoV-2 titres are detectable in the first week of illness with an early  
49 peak observed at symptom onset to day 5 of illness. This review underscores the importance of  
50 early case finding and isolation, as well as public education on the spectrum of illness. However,  
51 given potential delays in the isolation of patients, effective containment of SARS-CoV-2 may be  
52 challenging even with an early detection and isolation strategy.

53 **Funding:** No funding was received.

54

## 55 INTRODUCTION

56 Viral load kinetics and the duration of viral shedding are important determinants for disease  
57 transmission. They determine the duration of infectiousness which is a critical parameter to inform  
58 effective control measures and disease modelling. While a number of studies have evaluated  
59 SARS-CoV-2 shedding, viral load dynamics and duration of viral shedding reported across studies  
60 so far have been heterogenous.<sup>1</sup> In several case series with serial respiratory sampling, peak viral  
61 load was observed just before, or at the time of symptom onset.<sup>2-4</sup> Viral ribonucleic acid (RNA)  
62 shedding was reported to be persistent in the upper respiratory tract and in faeces, for over one  
63 month after illness onset.<sup>1</sup> However, the duration of SARS-CoV-2 RNA detection has not been well  
64 characterised. A comprehensive understanding of viral load dynamics, length of viral shedding,  
65 and how these relate to other factors, such as age and disease severity is lacking.

66 The aim of this systematic review and meta-analysis was to i) characterise the viral load dynamics  
67 of SARS-CoV-2, duration of viral RNA shedding by reverse transcriptase polymerase chain  
68 reaction (RT-PCR) and viable virus shedding in various body fluids and ii) compare SARS-CoV-2  
69 viral dynamics with that of SARS-CoV-1 and MERS-CoV.

## 70 METHODS

### 71 *Search Strategy*

72 We retrieved all articles reporting viral dynamics and/or the duration of shedding of SARS-CoV-2,  
73 SARS-CoV-1 or MERS-CoV in various specimens through systematic searches of major  
74 databases including Medline, EMBASE, Europe PMC, pre-print databases (MedRxiv, BioRxiv) and  
75 the grey literature from 1 January 2003 to 6<sup>th</sup> June 2020 using Medical Subject Headings (MeSH)  
76 terms (Supplementary Material). We also manually screened the references of included original  
77 studies to obtain additional studies. Studies prior to 2003 were excluded since the first recognised  
78 case of SARS-CoV-1 was identified in March 2003.

79 This systematic review was registered in PROSPERO on 29<sup>th</sup> April 2020 (CRD42020181914) and  
80 will be updated in three monthly intervals as a living systematic review.

### 81 *Study Selection*

82 Studies were eligible if they met the following inclusion criteria: (1) report on SARS-CoV-2, SARS-  
83 CoV-1 or MERS-CoV infection and (2) report viral load kinetics, duration of viral shedding or viable  
84 virus. We excluded: (1) review papers; (2) animal studies; (3) studies on environmental sampling;  
85 (4) case reports and case series with < 5 participants, due to likely reporting bias; (5) papers where  
86 the starting point of viral shedding was not clear or reported from post-discharge and (6) modelling  
87 studies with no original data.

### 88 ***Data Extraction***

89 Two authors (MT and OL) screened and retrieved articles according to the eligibility criteria. Four  
90 reviewers (MT, OL, JS, MC) performed full text review and final article selection. From each study,  
91 the following variables were extracted as a minimum: name of first author, year of publication, city  
92 and country, sample size, median age, sex ratio, time from symptom onset to viral clearance  
93 detected by RT-PCR and culture in different specimens, and longest reported time to viral  
94 clearance. If these data were not reported, we also contacted the authors to request the data. If  
95 available, we extracted data on peak viral load, clinical outcome, and reported factors associated  
96 with duration of viral shedding.

### 97 ***Risk of bias in included studies***

98 Two authors (OL and JS) independently assessed study quality and risk of bias using the Joanna  
99 Briggs Institute (JBI) Critical Appraisal Checklist tools,<sup>5</sup> which comprise standardised checklists,  
100 for the different study designs included in this review. Any disagreements regarding grading of  
101 quality were resolved through discussion with a third author (MC).

### 102 ***Meta-Analysis***

103 For every study included, mean duration of viral shedding and 95% confidence interval (CI) were  
104 calculated. The random-effects model (DerSimonian or Laird) was applied to estimate a pooled  
105 effect size. Forest plots illustrated the detailed representation of all studies based on the effect size  
106 and 95% CI. If not reported, means and standard deviations were derived from sample size,  
107 median, interquartile range (IQR), minimum and maximum values.<sup>6</sup> Heterogeneity between studies  
108 were quantified by the  $I^2$  index and Cochran's Q test. Publication bias was not assessed as usual

109 appraisal methods are uninformative when meta-analysed studies do not include a test of  
110 significance. A weighted meta-regression using an unrestricted maximum likelihood model was  
111 performed to assess the impact of potential moderators on the pooled effect size (P-values <0.05  
112 were considered significant). All statistical analyses were performed using Comprehensive Meta-  
113 Analysis (CMA) version 3 software (Biostat, Englewood, mNJ).

## 114 **RESULTS**

115 The systematic search identified 1486 potentially relevant articles. Three hundred and fifty articles  
116 were retrieved for full text review. After reviewing the eligibility criteria, a total of 79 studies on  
117 SARS-CoV-2, eight on SARS-CoV-1, and 11 on MERS-CoV were included (Figure 1).

### 118 **Summary of SARS-CoV-2 studies**

119 Of the 79 papers included, 58 studies were conducted in China (Table 1). Six studies included  
120 outpatient or community cases, the remainder comprised hospitalised patients only. Six studies  
121 reported viral load dynamics exclusively in children.<sup>7-12</sup> Two additional studies included children,  
122 but data on viral load dynamics were presented in aggregate with adults.<sup>13,14</sup> One study reported  
123 findings in renal transplant patients.<sup>15</sup>

### 124 **Median duration of viral shedding**

125 In total, 61 studies reported median or maximum viral RNA shedding in at least one body fluid  
126 and six studies provided duration of shedding stratified by illness severity only. Of those, 43  
127 (3229 individuals) reported duration of shedding in upper respiratory tract (URT), seven (260  
128 individuals) in lower respiratory tract (LRT), 13 (586 individuals) in stool, and 2 studies (108  
129 individuals) in serum samples were eligible for quantitative analysis. Means viral shedding  
130 durations were 17.0 days (95% CI, 15.5-18.6), 14.6 days (95% CI, 9.3-20.0), 17.2 days (95% CI,  
131 14.4-20.1) and 16.6 days (95% CI, 3.6-29.7), respectively (Figures 2 to 5). Maximum duration of  
132 RNA shedding reported in URT, LRT, stool and serum was 83, 59, 35 and 60 days, respectively.

133 Studies reporting duration of viral shedding in URT and stool samples were eligible for meta-  
134 regression analysis. Pooled mean viral shedding duration was positively associated with age

135 (slope: +0.304; 95% CI, +0.115 to +0.493;  $p = 0.002$  Fig 6), but not gender ( $p = 0.277$ ,  
136 Supplementary Fig 3). When adjusted for the proportion of male subjects in a multivariable  
137 analysis, mean age was positively associated with the mean duration of viral shedding in URT  
138 specimens ( $p = 0.003$ ). There was a positive but non-significant association between mean age  
139 and duration of shedding in stool ( $p=0.37$ ) (Supplementary Fig 4).

#### 140 **Peak viral load**

141 The majority of studies evaluating SARS-CoV-2 viral load in serial URT samples demonstrated  
142 peak viral loads within the first week of symptom onset.<sup>2,4,8,16-24</sup> The highest viral loads were  
143 reported either soon after or at the time of symptom onset<sup>2,8,16,23,24</sup> or at day 3-5 of illness<sup>4,18,20,22</sup>  
144 followed by a consistent decline.

145 Five studies that evaluated viral load dynamics in LRT samples observed a peak viral load in the  
146 second week of illness.<sup>4,18,20,23,25</sup> In contrast, the dynamics of SARS-CoV-2 shedding in stool is  
147 more erratic, with highest viral loads reported on day 7,<sup>18</sup> 2-3 weeks,<sup>24,25</sup> and up to 5-6 weeks  
148 after symptom onset.<sup>23</sup> While several studies reported significantly higher viral titres in stool  
149 compared to respiratory samples,<sup>8,25</sup> Huang *et al.* reported lower viral load in stool than in both  
150 LRT and URT samples early in the disease course.<sup>23</sup>

151

#### 152 **Severity and association with duration of viral shedding**

153 In total, 20 studies evaluated duration of viral RNA shedding based on disease severity. The  
154 majority ( $n=13$ ) reported longer duration of viral shedding in patients with severe illness than  
155 those with non-severe illness,<sup>18,25-36</sup> while five studies reported similar shedding durations  
156 according to disease severity in URT samples<sup>17,19,37-39</sup> and one study in stool samples.<sup>40</sup> Only  
157 one study reported shorter viral shedding in moderate to severe illness compared to mild to  
158 moderate illness.<sup>41</sup> Six studies have performed comparative analysis based on severity of  
159 illness;<sup>18,25,27,28,38,39</sup> the majority ( $n=5$ ) demonstrated significantly longer duration of shedding  
160 among the severe illness group compared to the non-severe patients and only one study  
161 observed no difference.<sup>39</sup> (Table 2).

## 162 **Other factors associated with prolonged shedding**

163 All but one study<sup>42</sup> (n=10) that examined the impact of age on SARS-CoV-2 shedding identified  
164 an association between older age and prolonged viral RNA shedding.<sup>25,26,28,33,37-39,43-45</sup> Three  
165 studies identified age as an independent risk factor for delayed viral clearance.<sup>25,26,38</sup> Male sex  
166 was also associated with prolonged shedding,<sup>25,38,46</sup> and the association remained significant  
167 even when patients were stratified based on illness severity.<sup>25,38</sup> Corticosteroid treatment was  
168 associated with delayed viral clearance in four studies,<sup>33,38,47,48</sup> and one study that recruited 120  
169 critically ill patients, found no difference between corticosteroid and control groups.<sup>49</sup>

170 In a phase 2 open-label study evaluating interferon beta-1b, lopinavir–ritonavir, and ribavirin a  
171 shorter duration of viral shedding was seen with combination treatment compared to the  
172 control.<sup>50</sup> None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir)  
173 independently improved viral RNA clearance.<sup>28,51</sup> In a retrospective study of 284 patients,  
174 lopinavir/ritonavir use was associated with delayed viral clearance even after adjusting for  
175 confounders.<sup>28</sup>

## 176 **Asymptomatic SARS-CoV-2 shedding**

177 Twelve studies reported on viral load dynamics and/or duration of viral shedding among patients  
178 with asymptomatic SARS-CoV-2 infection (Table 3); two demonstrated lower viral loads among  
179 asymptomatic patients compared to symptomatic patients,<sup>8,52</sup> while four studies found similar  
180 initial viral loads.<sup>13,14,53,54</sup> However, Chau *et al* reported significantly lower viral load in  
181 asymptomatic patients during the follow up compared to symptomatic patients.<sup>53</sup> Faster viral  
182 clearance was observed in asymptomatic individuals in five out of six studies.<sup>13,28,53,55,56</sup> The  
183 exception Yongchen *et al.*, found longer shedding duration among asymptomatic cases, but the  
184 difference was not significant.<sup>36</sup>

## 185 **Live virus detection**

186 We identified 11 studies that attempted to isolate live virus. All eight studies that attempted virus  
187 isolation in respiratory samples successfully cultured viable virus within the first week of illness,  
188 <sup>9,17,20,54,57-60</sup> No live virus was isolated from any respiratory samples taken after day 8 of symptoms

189 in three studies,<sup>20,57,58</sup> or beyond day 9 in two studies<sup>17,54</sup> despite persistently high viral RNA loads.  
190 One study demonstrated the highest probability of positive culture on day 3 of symptoms.<sup>57</sup> Arons  
191 *et al.* cultured viable virus 6 days before typical symptom onset, however onset of symptom was  
192 unclear.<sup>54</sup>

193 The success of viral isolation correlated with viral load quantified by RT-PCR. No successful viral  
194 culture was obtained from samples with a viral load below 10<sup>6</sup> copies/ml,<sup>20</sup> Ct values >24,<sup>57</sup>  
195 or >34,<sup>54,58</sup> with culture positivity declining with increasing Ct values.<sup>58</sup> Several other studies  
196 cultured live virus from RT-PCR positive specimens; however, they did not correlate these results  
197 with viral load titres.<sup>9,59,60</sup>

198 Only one study reported the duration of viable virus shedding in respiratory samples; the median  
199 time to clearance from URT and LRT samples was 3.5 and 6 days, respectively.<sup>20</sup> Arons *et al.*  
200 cultured viable virus in one out of three asymptomatic cases from the respiratory tract.<sup>54</sup>

201 Of 3 studies attempting to isolate viable virus from stool,<sup>20,61</sup> culture was successful in two of  
202 three RNA-positive patients in one study, but the time points from symptom onset were not  
203 reported.<sup>62</sup> Andersson *et al.* failed to culture virus from 27 RT-PCR positive serum samples.<sup>63</sup>

#### 204 **Summary of SARS-CoV-1 and MERS studies**

205 Eight studies on SARS-CoV-1 were included; the majority of studies did not report mean or median  
206 duration of viral shedding thus, were not eligible for quantitative analysis. The maximum duration  
207 of viral shedding reported was 8 weeks in URT,<sup>64,65</sup> 52 days in LRT,<sup>61,64</sup> 6-7 weeks in serum,<sup>66</sup>  
208 and 126 days in stool samples.<sup>61,64,67-69</sup> Dialysis patients had longer viral shedding in stool  
209 compared to non-dialysis patients.<sup>68</sup> Studies that have evaluated SARS-CoV-1 kinetics found low  
210 viral load in the initial days of illness, increasing after the first week of illness in URT samples,  
211 peaking at day 10,<sup>70</sup> or day 12-14,<sup>67</sup> and declining after week 3-4.<sup>65</sup> High viral loads correlated with  
212 severity of illness<sup>65</sup> and poor survival.<sup>65</sup> While Chen *et al.* identified an association between  
213 younger age and lower viral titers,<sup>65</sup> Leong *et al.* found no difference.<sup>69</sup> Viable SARS-CoV-1 was  
214 isolated from stool and respiratory samples up to 4 weeks, and urine specimens up to day 36.<sup>64,66</sup>  
215 All attempts to isolate virus from RT-PCR-positive stool specimens collected >6weeks after



216 disease onset failed.<sup>61</sup> The isolation probability for stool samples was approximately 5 to 10  
217 times lower compared to respiratory specimens.<sup>64</sup>

218 We identified 11 studies on MERS-CoV. Three studies (324 subjects) reporting MERS-CoV  
219 shedding in URT and four studies (93 subjects) in LRT were included in the quantitative analysis.  
220 The mean shedding duration was 15.3 days (95% CI, 11.6 – 19.0) and 16.6 days (95% CI, 14.8 –  
221 18.4), respectively (Supplementary Figures 1 and 2). Only one study reported duration of viral  
222 shedding in serum with a median of 14 days and max of 38 days.<sup>71</sup> In a small study, mortality rates  
223 were higher in patients with viraemia.<sup>72</sup> In URT and LRT specimens, prolonged shedding was  
224 associated with illness severity<sup>73,74</sup> and survival<sup>75</sup> with the shortest duration observed in  
225 asymptomatic patients.<sup>73</sup> Peak viral loads were observed between days 7 to 10 and higher viral  
226 loads was observed among patients with severe illness and fatal outcome.<sup>71,73,74,76,77</sup> Differences  
227 in viral loads between survivors and fatal cases was more pronounced in the second week of  
228 illness ( $P < .0006$ ).<sup>77</sup> The proportion of successful viable culture was 6% in respiratory samples  
229 with a viral load values below  $10^7$  copies/ml.<sup>78</sup>

### 230 **Qualitative analysis**

231 All but 11 studies (6 cohort studies, 2 cross-sectional studies, and 1 RCT on SARS-CoV-2 and 2  
232 cohort studies on MERS-CoV) were case series, the majority of which recruited non-consecutive  
233 patients and therefore prone to possible selection bias. (Supplementary Table 1)

### 234 **DISCUSSION**

235 This systematic review and meta-analysis provide comprehensive data on the viral dynamics of  
236 SARS-CoV-2 including the duration of RNA shedding and viable virus isolation. Our findings  
237 suggest that while patients with SARS-CoV-2 may have prolonged RNA shedding, median time  
238 to live virus clearance from upper and lower respiratory tract samples were 3.5 days and 6 days  
239 respectively. No live virus isolated beyond day nine of symptoms despite persistently high viral  
240 RNA loads, thus emphasising that the infectious period cannot be inferred from the duration of  
241 viral RNA detection. This finding is supported by several studies demonstrating a relationship

242 between viral load and viability of virus, with no successful culture from samples below a certain  
243 viral load threshold.

244 SARS-CoV-2 viral load appears to peak in the URT within the first week of illness, and later in  
245 the LRT. In contrast, peaks in SARS-CoV-1 and MERS-CoV viral loads in the URT occurred at  
246 days 10-14 and 7-10 days of illness, respectively. Combined with viable isolation in respiratory  
247 samples within the first week of illness, patients with SARS-CoV-2 infection are likely to be most  
248 infectious in the first week of illness. Several studies report viral load peaks during the prodromal  
249 phase of illness or at the time of symptom onset,<sup>2,4,8,16-23</sup> providing a rationale for the efficient  
250 spread of SARS-CoV-2. This is supported by the observation in contact tracing studies that the  
251 highest risk of transmission occurs during the prodromal phase or early in the disease  
252 course.<sup>79,80</sup> No secondary cases were identified beyond 5 days after the symptom onset.<sup>81</sup>  
253 Although modelling studies estimated potential viral load peak before symptom onset, we did not  
254 identify any study that confirms pre-symptomatic viral load peak.<sup>16</sup>

255 Emerging evidence suggests a correlation between virus persistence and disease severity and  
256 outcome.<sup>18,25,27-29,38</sup> This is consistent with the viral load dynamics of influenza, MERS-CoV, and  
257 SARS-CoV-1 whereby severity of illness was also associated with prolonged viral  
258 shedding.<sup>73,74,82</sup> However, more studies are needed to understand the duration of viable virus in  
259 patients with severe illness.

260 Similar to SARS-CoV-1, SARS-CoV-2 can be detected in stool for prolonged periods, with high  
261 viral loads detected even after 3 weeks of illness. A clear difference between SARS-CoV and  
262 MERS-CoV is the detection of viral RNA in stool. In SARS-CoV-1, RNA prevalence in stool  
263 samples was high, with almost all studies reporting shedding in stool. Although viable SARS-CoV-  
264 1 was isolated up to 4 weeks of illness, faecal-oral transmission was not considered to be a primary  
265 driver of infection. Whereas in MERS-CoV, none of the studies reported duration of viral shedding  
266 in stool and RNA detection was low.<sup>77,83</sup> To date, only a few studies demonstrated viable SARS-  
267 CoV-2 in stool.<sup>62,84</sup> Thus, the role of faecal shedding in viral transmission remains unclear.

268 Although viral loads at the start of infection appear to be comparable between asymptomatic and  
269 symptomatic patients infected with SARS-CoV-2, most studies demonstrate faster viral clearance

270 among asymptomatic individuals. This suggests similar transmission potential among both  
271 groups at the onset of infection, but a shorter period of infectiousness in asymptomatic patients.  
272 This is in keeping with viral kinetics observed with other respiratory viruses such as influenza and  
273 MERS-CoV, in which people with asymptomatic infection have a shorter duration of viral  
274 shedding than symptomatic individuals.<sup>73,85</sup> However, there are limited data on the shedding of  
275 infectious virus in asymptomatic individuals to quantify their transmission potential.

276 We identified a systematic review of SARS CoV-2 viral load kinetics that included studies  
277 published up until 12 May 2020.<sup>86</sup> This review included many studies that did not meet our  
278 eligibility criteria, including 26 case reports and 13 case series involving <5 individuals; these are  
279 prone to significant selection bias, reporting atypical cases with prolonged viral shedding.  
280 Additionally, the review included studies that reported viral shedding duration from the time of  
281 hospital admission or initial PCR positivity, rather than symptom onset. Furthermore, no meta-  
282 analysis of the duration of viral shedding was performed.

283 This is the first study that has comprehensively examined and compared SARS-CoV-2, SARS-  
284 CoV-1 and MERS-CoV viral dynamics and performed a meta-analysis of viral shedding duration.  
285 Our study has limitations. First, some patients in the included studies received a range of  
286 treatments, including steroids and antivirals, which may have modified the shedding dynamics.  
287 Second, most of the included studies are case series, which are particularly vulnerable to  
288 selection bias. Third, our meta-analysis identified substantial study heterogeneity, likely due to  
289 differences in study population, follow up and management approaches. Further, shedding  
290 duration is reported as median  $\pm$  IQR for most studies, but meta-analysis necessitates  
291 conversion to mean  $\pm$  SD.<sup>6</sup> The validity of this conversion is based on the assumption that  
292 duration of viral shedding is normally distributed, which may not apply to some studies.

293 In conclusion, although SARS-CoV-2 RNA shedding can be prolonged in respiratory and stool  
294 samples, the duration of viable virus is short-lived, with culture success associated with viral load  
295 levels. No study has reported live SARS-CoV-2 beyond day nine. Most studies detected the  
296 SARS-CoV-2 viral load peak within the first week of illness. These findings highlight that isolation  
297 practices should be commenced with the start of first symptoms including mild and atypical

298 symptoms that precede more typical COVID-19 symptoms. This systematic review underscores  
299 the importance of early case finding and isolation, as well as public education on the spectrum of  
300 illness. However, given potential delays in the isolation of patients, effective containment of  
301 SARS-CoV-2 may be challenging even with an early detection and isolation strategy.<sup>87</sup>

302

### 303 **Authors contributions:**

304 M. Cevik: conceptualisation, methodology, investigation, data curation, writing – original draft. M.  
305 Tate: investigation, data curation, writing – original draft; O Lloyd: investigation, data curation,  
306 writing – review and editing; A. E. Maraolo: formal analysis, writing – original draft; J. Schafers:  
307 investigation, data curation, writing – review and editing; A Ho: conceptualisation, methodology,  
308 data curation, writing – original draft, supervision.

309

### 310 **Financial support and sponsorship**

311 No financial support received

312

### 313 **Conflicts of interest**

314 All authors have nothing to disclose.

**Table 1: Summary of included studies**

Study	Geographical location	Study setting	Study design	Number of patients	Age Median (IQR)	Male sex N (%)	Specimen types
<b>SARS-CoV-2</b>							
Andersson et al. <sup>63</sup>	Oxford, UK	Hospital	Case series	167	56 (46-76)	89 (53)	Serum
Arons et al. <sup>54</sup>	King's County, USA	Care home	Cross-sectional	46	78.6 ± 9.5*	NR	URT
Bullard et al. <sup>57</sup>	Manitoba, Canada	Hospital	Case series	90	45 (30-59)	44 (49)	Respiratory samples (not specified)
Cai et al. <sup>7</sup>	Shanghai/ Hefei/ Qingdao, China	Hospital	Case series	10	6	4 (40)	LRT, blood, stool, urine
Cai et al. <sup>26</sup>	Shenzhen, China	Hospital	Case series	298	47 (33-61)	149 (50)	URT
Chang et al. <sup>88</sup>	Beijing, China	Hospital	Case series	16	35.5 (24-53)	11 (69)	URT
Chau et al. <sup>53</sup>	Ho Chi Minh City, Vietnam	Hospital	Case series	30	29 (16-60)	15 (50)	URT
Chen et al. <sup>27</sup>	Shanghai, China	Hospital	Case series	249	51 (36-64)	126 (51)	URT
Chen et al. <sup>89</sup>	Wuhan, China	Hospital	Case series	25	51.4 ±16.6*	11 (44)	URT
Chen et al. <sup>28</sup>	Guangzhou, China	Hospital	Case series	284	48 (33-62)	131 (46)	URT
Chen et al. <sup>29</sup>	Wuhan, China	Hospital	Case series	42	51	15 (36)	URT, stool, urine
Corman et al. <sup>90</sup>	Germany	Hospital	Case series	18	NR	12 (67)	Blood
Fan et al. <sup>30</sup>	Shenyang, China	Hospital	Case series	55	46.8	30 (55)	URT, sputum
Fang et al. <sup>31</sup>	Xiangtan, China	Hospital	Case series	32	41	16 (50)	URT, stool, blood
Fu et al. <sup>91</sup>	Huazhong, China	Hospital	Case series	50	64 (37-87)	27 (54)	URT
Han et al. <sup>8</sup>	Chongqing, South Korea	Hospital	Case series	12	6.5 (0.007-16)	5 (42)	URT, stool
He et al. <sup>16</sup>	Guangzhou, China	Hospital	Case series	94	46	47 (50)	URT
Hu et al. <sup>37</sup>	Qingdao, China	Hospital	Case series	59	46 (33-57)	28 (47)	URT
Hu et al. <sup>55</sup>	Nanjing, China	Hospital	Case series	24	32.5 (21-57)	8 (33)	URT
Huang et al. <sup>51</sup>	Guangzhou, China	Hospital	Case series	27	NR	12 (44)	URT

<b>Huang et al.</b> <sup>23</sup>	Wenzhou, China	Hospital	Case series	33	47 (range 2-84)	17 (52)	URT, LRT, stool
<b>Huang et al.</b> <sup>92</sup>	Wuhan, China	Hospital	Retrospective cohort	200	58± 17*	115 (48)	URT
<b>Hung et al.</b> <sup>50</sup>	Hong Kong	Hospital	RCT	127	52 (32-62)	68 (54)	URT, stool
<b>Kim et al.</b> <sup>4</sup>	Soeul/ Incheon/ Seongna, South Korea	Hospital	Case series	28	40 (28-54)	15 (54)	URT, LRT
<b>Kujawski et al.</b> <sup>17</sup>	6 states, USA	Hospital /Outpatient	Case series	12	53 (range 21- 68)	8 (75)	URT, LRT, stool, blood, urine
<b>L'Huillier et al.</b> <sup>9</sup>	Geneva, Switzerland	Hospital	Case series	23	12 (3.8-14.5)	NR	URT
<b>La Scola et al.</b> <sup>58</sup>	France	Hospital	Case series	155	NR	NR	URT, LRT
<b>Lavezzo et al.</b> <sup>14</sup>	Vo', Italy	Community	Cross-sectional	Only sample # reported	Mixed	Mixed	URT
<b>Le et al.</b> <sup>59</sup>	Hanoi, Vietnam	Hospital	Case series	12	29.5*	3 (25)	URT
<b>Li et al.</b> <sup>93</sup>	Wuhan China	Hospital	Case series	36	57.5 (52-65)	23 (64)	URT
<b>Liang et al.</b> <sup>49</sup>	Wuhan, China	Hospital	Case series	120	61.5 (47-70)	68 (57)	URT
<b>Ling et al.</b> <sup>47</sup>	Shanghai, China	Hospital	Case series	66	44 (16-778)	38 (58)	URT, stool, blood, urine
<b>Liu et al.</b> <sup>94</sup>	Wuhan, China	Hospital	Case series	238	55 (38.3-65)	138 (58)	URT
<b>Liu et al.</b> <sup>32</sup>	Nanchang, China	Hospital	Case series	76	48.3	48 (63)	URT
<b>Lo et al.</b> <sup>95</sup>	Macau, China	Hospital	Case series	10	54 (27-64)	3 (30)	URT, LRT, stool, urine
<b>Lou B et al.</b> <sup>96</sup>	Zhejiang, China	Hospital	Case series	80	55 (45-64)	50 (69)	LRT
<b>Pongpirul et al.</b> <sup>97</sup>	Bangkok, Thailand	Hospital	Case series	11	61 (28-74)	6 (55)	URT
<b>Qian et al.</b> <sup>98</sup>	Ningbo, China	Hospital	Case series	24	NR	NR	URT
<b>Quan et al.</b> <sup>99</sup>	Wuhan/Shenzhen/ Xiangyang, China	Hospital	Case series	23	60.3 ±15.3*	23 (100)	Prostatic secretions all negative (URT)

<b>Sakurai et al.</b> <sup>43</sup>	Aichi, Japan	Hospital	Case series	90	59.5 (36-68)	53 (59)	URT
<b>Seah et al.</b> <sup>100</sup>	Singapore	Hospital	Case series	17	NR	NR	Tears
<b>Shastri et al.</b> <sup>46</sup>	Mumbai, India	Reference lab	Case series	68	37 (range 3-75)	48 (71)	URT
<b>Shi et al.</b> <sup>33</sup>	Wuhan, China	Hospital	Case series	246	58 (47-67)	126 (51)	URT
<b>Song et al.</b> <sup>101</sup>	Nanjing, China	Hospital	Case series	13	22 – 67 (range only)	13 (100)	URT, semen, testicular sample
<b>Song et al.</b> <sup>102</sup>	Beijing, China	Hospital/Outpatient	Case series	21	37 (21-59.5)	8 (38)	URT
<b>Talmy et al.</b> <sup>44</sup>	Ramat Gan, Israel	Outpatient	Case series	119	21 (19-25)	84 (71)	URT
<b>Tan et al.</b> <sup>34</sup>	Chongqing, China	Hospital	Case series	142	NR	NR	URT
<b>Tan et al.</b> <sup>18</sup>	Chongqing, China	Hospital	Case series	67	49 (10-77)	35 (52)	URT, LRT, stool, blood, urine
<b>Tan et al.</b> <sup>10</sup>	Changsha, China	Hospital	Case series	10	7 (1-12)	3 (30)	URT, stool
<b>Tian et al.</b> <sup>41</sup>	Beijing, China	Hospital/Outpatient	Case series	75	41.5 (range 0.8 – 88)*	42 (56)	Respiratory tract sample (not specified further)
<b>To et al.</b> <sup>19</sup>	Hong Kong, China	Hospital	Case series	23	62 (37-75)	13 (57)	URT, stool, blood, urine
<b>To et al.</b> <sup>60</sup>	Hong Kong, China	Hospital	Prospective Cohort	12	62.5 (37-75)	7 (58)	URT (saliva)
<b>Tu et al.</b> <sup>103</sup>	Anhui, China	Hospital	Case series	40	Viral shedding <10 days: 40.86 ± 8.26 Viral shedding ≥10 days: 45.5 ± 14.60	21 (53)	URT
<b>Wang et al.</b> <sup>104</sup>	Henan, China	Hospital	Case series	18	39 (29-55)	10 (56)	URT
<b>Wang et al.</b> <sup>105</sup>	Jinhua, China	Hospital	Case series	17	42 ±17*	10 (59)	URT, stool
<b>Wölfel et al.</b> <sup>20</sup>	Munich, Germany	Hospital	Case series	9	NR	NR	URT, blood, urine
<b>Wu et al.</b> <sup>106</sup>	Hainan, China	Hospital	Case series	91	50 (range 21-83)*	52 (57)	URT, stool

<b>Wu et al.</b> <sup>11</sup>	Qingdao, China	Hospital	Case series	74	6 (0.1-15.08 range)	44 (59)	Stool
<b>Wu et al.</b> <sup>40</sup>	Zhuhai, China	Hospital	Case series	74	43.8*	35 (47)	Stool
<b>Wyllie et al.</b> <sup>21</sup>	New Haven, USA	Hospital	Case series	44	61 (23-92 range)*	23 (52)	URT (saliva)
<b>Xiao et al.</b> <sup>45</sup>	Wuhan, China	Hospital	Case series	56	55 (42-68)	34 (61)	URT
<b>Xiao et al.</b> <sup>62</sup>	Guangzhou, China	Hospital	Case series	28			Stool
<b>Xu et al.</b> <sup>38</sup>	Shenzhen/ Zhejiang, China	Hospital	Retrospective Cohort	113	52 (42-63)	66 (58)	URT
<b>Xu et al.</b> <sup>107</sup>	Shenyang, China	Hospital	Case series	14	48 ± 13.4*	7 (50)	URT, LRT, serum, conjunctiva
<b>Xu et al.</b> <sup>12</sup>	Guangzhou, China	Hospital	Case series	10	6.6	6 (60)	URT, rectal swab
<b>Yan et al.</b> <sup>39</sup>	Hubei, China	Hospital	Case series	120	52 (35-63)	54 (45)	URT
<b>Yang et al.</b> <sup>56</sup>	Wuhan, China	Hospital	Case series	78 (45 symptomatic)	Symptomatic: 56 (34-63) Asymptomatic: 37 (26-45)	Symptomatic: 31 (40) Asymptomatic: 11 (33)	URT
<b>Yang et al.</b> <sup>108</sup>	Shenzhen, China	Hospital	Case series	213	52 (range 2-86)	108 (51)	URT, LRT
<b>Yongchen et al.</b> <sup>36</sup>	Nanjing, Xuzhou, China	Hospital	Case series	21	37	13 (62)	URT, stool
<b>Young et al.</b> <sup>22</sup>	Singapore	Hospital	Case series	18	47	9 (50)	URT, stool, blood, urine
<b>Zha et al.</b> <sup>48</sup>	Wuhu, China	Hospital	Case series	31	39 (32-54)	20 (65)	URT
<b>Zhang et al.</b> <sup>24</sup>	Beijing, China	Hospital	Case series	23	48 (40-62)	12 (52)	URT, stool, blood, urine
<b>Zhang et al.</b> <sup>13</sup>	Shenzhen, China	Hospital	Case series	56	Mixed	Mixed	URT, stool
<b>Zheng et al.</b> <sup>25</sup>	Zhejiang, China	Hospital	Retrospective Cohort	96	53 (33.4-64.8)	NR	LRT, stool, blood, urine
<b>Zhou et al.</b> <sup>42</sup>	Wuhan, China	Hospital	Case series	41	58 (48-62)	22 (54)	URT
<b>Zhou et al.</b> <sup>35</sup>	Wuhan, China	Hospital	Case series	191	56 (46-67)	119 (62)	URT
<b>Zhou et al.</b> <sup>52</sup>	Guangzhou, China	Hospital	Case series	31	45 (33-60) 37 (28-57)	4 (44) 6 (27)	URT
<b>Zhu et al.</b> <sup>15</sup>	Wuhan, China	Hospital	Case series	10	49.5	8 (80)	URT



<b>Zou et al.<sup>2</sup></b>	Zhuhai, China	Hospital/outpatient	Case series	18	59 (range 26-76)	9 (50)	URT
<b>SARS-CoV-1</b>							
<b>Chan et al.<sup>64</sup></b>	Hong Kong, China	Hospital	Case series	415	11.3 ± 4.1* 37.1 ± 11.2*	132 (33)	URT, LRT, stool, urine
<b>Chen et al.<sup>65</sup></b>	Taiwan	Hospital	Case series	108	Stratified	95	URT
<b>Cheng et al.<sup>67</sup></b>	Hong Kong, China	Hospital	Case series	1041	NR	NR	URT, LRT, stool, urine
<b>Kwan et al.<sup>68</sup></b>	Hong Kong, China	Hospital	Case series	12 dialysis 33 controls	Dialysis: 58 (range 34-74);* Controls: 57 (range 34-75)	6 (50)	URT, stools, urine
<b>Liu et al.<sup>61</sup></b>	Beijing, China	Hospital	Case series	56	31 (male) 34 (female)	31 (55)	LRT, stool
<b>Leong et al.<sup>69</sup></b>	Singapore	Hospital	Case series	64	35.2 (17-63 range)*	16 (25)	URT, stool, blood, urine
<b>Peiris et al.<sup>70</sup></b>	Hong Kong, China	Hospital	Case series	75	39.8 (SD 12.2)	0.92	URT
<b>Xu et al.<sup>109</sup></b>	Beijing, China	Hospital	Case series	54	NR	NR	LRT, blood, urine
<b>MERS-CoV</b>							
<b>Al Hosani et al.<sup>73</sup></b>	Abu Dhabi, UAE	Hospital/community	Case series	65	20 -59	43 (66)	LRT
<b>Al-Jasser et al.<sup>110</sup></b>	Riyadh, Saudi Arabia	Hospital	Case series	167	46.71*	142 (57)	URT
<b>Alkendi et al.<sup>111</sup></b>	Tawam/Al Ain, UAE	Hospital	Case series	58	43.5	41 (71)	URT
<b>Arabi et al.<sup>75</sup></b>	Saudi Arabia	Hospital	Cohort	330	58 (44-69)	225 (68)	URT
<b>Corman et al.<sup>77</sup></b>	Riyadh, Saudi Arabia	Hospital	Case series	37	69 (24-90)*	27 (39)	URT, LRT, stool, blood, urine
<b>Hong et al.<sup>76</sup></b>	Seoul, South Korea	Hospital	Case series	30	49*	19 (63)	Blood
<b>Min et al.<sup>71</sup></b>	Seoul/others, South Korea	Hospital	Case series	14	62	6 (35)	LRT, serum
<b>Muth et al.<sup>78</sup></b>	Riyadh, Saudi Arabia	Hospital	Case series	32	66 (24-90)	24 (75)	LRT
<b>Oh et al.<sup>74</sup></b>	Seoul, South Korea	Hospital	Case series	17	NR	NR	URT, LRT, serum
<b>Park et al.<sup>112</sup></b>	Seoul, South Korea	Hospital	Case series	17	NR	NR	URT, LRT

---

<b>Shalhoub et al.<sup>72</sup></b>	Jeddah, Saudi Arabia	Hospital	Retrospective cohort	32	65	14 (44)	LRT, serum
-------------------------------------	----------------------	----------	----------------------	----	----	---------	------------

---

317 Abbreviations: UK, United Kingdom, USA; United States of America; UAE, United Arab Emirates; RCT, randomised controlled trial; URT, upper respiratory  
318 tract; LRT, lower respiratory tract; NR, not reported.

319 \* Mean  $\pm$  standard deviation (or range if stated).

320

321

322

323

324

325

326

327

328

329

330

331

332

333 **Table 2: Severity of illness and viral dynamics**

<b>Study</b>	<b>Classification of severity</b>	<b>Median duration - days (IQR)</b>	<b>Viral dynamics in severe patients compared to non-severe patients</b>	<b>P-value</b>
<b>Chen et al.<sup>27</sup></b>	ICU vs. non-ICU patients	11	Median time to viral clearance significantly longer in ICU vs. non-ICU patients (HR=3.17, 95% CI, 2.29-4.37)	Only HR provided
<b>Chen et al.<sup>28</sup></b>	China CDC guideline (version 7)	12 (8-16)	Shedding duration varies by severity: asymptomatic 6 days; mild 10 days; moderate 12 days; serious 14 days; critical 32 days	<0.0001
<b>Tan et al.<sup>18</sup></b>	China CDC guideline (version 6)	NP: 12 Any sample: 22	Viral shedding significantly longer in severe patients: any sample 23 vs. 20 days (note NP: 14 vs. 11 days – non-significant)	p=0.023 (any sample)
<b>Xu et al.<sup>38</sup></b>	WHO criteria	17 (13-32)	Higher proportion of severe patients had shedding >21 days (34.2% vs. 16.2%)	0.49
<b>Yan et al.<sup>39</sup></b>	China CDC guideline (version 6)	23 (18-32)	No difference in shedding duration (general 23 days vs. severe 26 days vs. critical 28 days)	0.51
<b>Zheng et al.<sup>25</sup></b>	China CDC guideline (version 6)	Resp: 18 (13-29)	Shedding duration significantly longer in severe patients (21 vs 14 days) in respiratory samples.  No difference in shedding duration in stool/serum	p=0.04

334 Abbreviations: IQR, interquartile range; ICU, intensive care unit; HR, hazard ratio; CDC, Centers  
 335 for Disease Control and Prevention; WHO, World Health Organization.

336

337

338

339

340

341


342

343 **Table 3: SARS-CoV-2 viral dynamics in asymptomatic patients compared to symptomatic**  
 344 **patients**

	<b>Median duration – days (IQR)</b>	<b>Viral dynamics in asymptomatic patients compared to symptomatic patients</b>	<b>P-value</b>
<b>Arons <i>et al.</i><sup>54</sup></b>	NR	No difference in viral load	NS
<b>Chau <i>et al.</i><sup>53</sup></b>	NR	Initial viral load similar. Asymptomatic patients had significantly lower viral load during the follow up compared to symptomatic patients and faster viral clearance in asymptomatic, compared to symptomatic individuals	0.027
<b>Chen <i>et al.</i><sup>28</sup></b>	6 (3.5-10)	Significantly shorter duration of viral shedding among asymptomatic cases (median 6 days, IQR 3.5-10), with increasing shedding duration associated with increasing illness severity	<0.0001
<b>Han <i>et al.</i><sup>8</sup></b>	NR	Symptomatic children had higher initial RNA load in nasopharyngeal swab specimens than asymptomatic children (9.01 vs. 6.32 log <sub>10</sub> copies/mL; p = 0.048).	0.048
<b>Hu <i>et al.</i><sup>55</sup></b>	6 (2-12)	Asymptomatic patients had shorter duration of viral shedding compared to pre-symptomatic patients (median duration of SARS-CoV-2 positivity was 6.0 (2.0 - 12.0) compared to 12.0 (12.0 - 14.0))	NR
<b>Lavezzo <i>et al.</i><sup>14</sup></b>	NR	No difference in viral load	NS
<b>Le <i>et al.</i><sup>59</sup></b>	9	NR	N/A
<b>Sakurai <i>et al.</i><sup>43</sup></b>	9 (6-11)	NR	N/A
<b>Yang <i>et al.</i><sup>56</sup></b>	8 (3-12)	Significantly shorter duration of viral shedding from nasopharynx swabs was observed among asymptomatic compared to symptomatic patients	P= .001
<b>Yongchen <i>et al.</i><sup>36</sup></b>	18 (5-28)	Longer shedding duration among asymptomatic cases (median 18 days, range 5-28), compared to non-severe (10 days, range 2-21) and severe (14 days, range 9-33) cases	NS
<b>Zhang <i>et al.</i><sup>13</sup></b>	9.63	Initial viral load similar, viral clearance occurred earlier in the asymptomatic (9.6 days) and symptomatic individuals (9.7 days, compared to pre-symptomatic group (13.6 days)	
<b>Zhou <i>et al.</i><sup>52</sup></b>	NR	Significantly higher viral load in symptomatic (n=22) compared to asymptomatic (n=9) patients (median cycle threshold (Ct) value 34.5 vs. 39.0, respectively) but duration of shedding was similar	

345 Abbreviations: IQR, interquartile range; RNA, ribonucleic acid; NR, not reported; NS, non-  
 346 significant; N/A, not applicable


**Figure 1.** Flowchart describing study selection



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).


**Figure 2:** Pooled mean duration (days) of SARS-CoV-2 shedding from the upper respiratory tract (random-effects model).



Note: the overall effect is plotted as a black square.

Test for heterogeneity: Q-value = 4076,08, df(Q) = 42,  $p < 0.001$ ,  $I^2 = 99\%$ .


**Figure 3:** Pooled mean duration (days) of SARS-CoV-2 shedding from the lower respiratory tract (random-effects model).



Note: the overall effect is plotted as a black square.

Test for heterogeneity: Q-value = 203.3, df(Q) = 6,  $p < 0.001$ ,  $I^2 = 97\%$ .


**Figure 4.** Pooled mean duration (days) of SARS-CoV-2 shedding in the blood (random-effects model).



Note: the overall effect is plotted as a black square.

Test for heterogeneity: Q-value = 77.6, df(Q) = 1,  $p < 0.001$ ,  $I^2 = 99\%$ .


**Figure 5.** Pooled mean duration (days) of SARS-CoV-2 shedding from the stool (random-effects model).



Note: the overall effect is plotted as a black square.

Test for heterogeneity: Q-value = 356.0, df(Q) = 12,  $p < 0.001$ ,  $I^2 = 96.6\%$ .

**Figure 6.** Meta-regression bubble plot of the impact of age on mean SARS-CoV-2 shedding from the upper respiratory tract



URT: upper respiratory tract.

Note: the plot was built upon 41 studies (no data on mean age from the study of Qian et al.<sup>98</sup>). A random-effects model was used.



## References:

1. Cevik M, Bamford C, Ho A. COVID-19 pandemic—a focused review for clinicians. *Clin Microbiol Infect* 2020; **26**(7): 842-7.
2. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* 2020; **382**(12): 1177-9.
3. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020.
4. Kim ES, Chin BS, Kang CK, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. *J Korean Med Sci* 2020; **35**(13): e142.
5. Institute TJB. The Joanna Briggs Institute Critical Appraisal tools for use in JBI systematic reviews—checklist for case series. , 2017.
6. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Medical Research Methodology* 2014; **14**(1): 135.
7. Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. *Clinical Infectious Diseases* 2020; **28**: 28.
8. Han MS, Seong M-W, Kim N, et al. Early Release - Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19, Seoul - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC.
9. L'Huillier A, Torriani G, Pigny F, Kaiser L, Eckerle I. Shedding of infectious SARS-CoV-2 in symptomatic neonates, children and adolescents. 2020.
10. Tan Y-p, Tan B-y, Pan J, Wu J, Zeng S-z, Wei H-y. Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China. *Journal of Clinical Virology* 2020; **127**: 104353.
11. Wu Q, Xing Y, Shi L, et al. Epidemiological and Clinical Characteristics of Children with Coronavirus Disease 2019. 2020.
12. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nature Medicine* 2020; **26**(4): 502-5.
13. Zhang Z, Xiao T, Wang Y, et al. Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers. *medRxiv* 2020: 2020.04.28.20083139.
14. Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature* 2020: 1-.
15. Zhu L, Gong N, Liu B, et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. *Eur Urol* 2020; **18**: 18.
16. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine*; **26**(5): 672-5.
17. Kujawski SA, Wong KK, Collins JP, et al. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. *Nature Medicine* 2020; **26**(6): 861-8.
18. Tan W, Lu Y, Zhang J, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. 2020.
19. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases* 2020; **20**(5): 565-74.
20. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020; **581**(7809): 465-9.
21. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs.

22. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. *JAMA* 2020; **03**: 03.
23. Huang J, Mao T, Li S, et al. Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study. *medRxiv* 2020: 2020.04.22.20071258.
24. Zhang N, Gong Y, Meng F, Bi Y, Yang P, Wang F. Virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients. 2020.
25. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* 2020; **369**.
26. Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy* 2020; **n/a**(n/a).
27. Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. *Journal of Infection* 2020; **80**(5): e1-e6.
28. Chen X, Zhang Y, Zhu B, et al. Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study.
29. Chen Y, Chen L, Deng Q, et al. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. *Journal of Medical Virology* 2020; **03**: 03.
30. Fan L, Liu C, Li N, et al. Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study.
31. Fang Z, Zhang Y, Hang C, Ai J, Li S, Zhang W. Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients. *Journal of Infection* 2020; **21**: 21.
32. Liu Y, Yan L-M, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis* 2020; **20**(6): 656-7.
33. Shi J, Cheng C, Yu M, et al. Systemic Inflammatory Cytokines Associate With SARS-COV-2 Viral Shedding Time in Covid-19 Inpatients. *ResearchSquare* 2020.
34. Tan L, Kang X, Ji X, et al. Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study. *Med* 2020.
35. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**(10229): 1054-62.
36. Yongchen Z, Shen H, Wang X, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. *Emerg* 2020; **9**(1): 833-6.
37. Hu X, Xing Y, Jia J, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. *Science of the Total Environment* 2020; **728** (no pagination).
38. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. *Clinical Infectious Diseases* 2020; **09**: 09.
39. Yan D, Liu X-y, Zhu Y-n, et al. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection.
40. Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol* 2020; **5**(5): 434-5.
41. Tian D, Wang L, Wang X, et al. Clinical research and factors associated with prolonged duration of viral shedding in patients with COVID-19. *ResearchSquare* 2020.
42. Zhou B, She J, Wang Y, Ma X. The duration of viral shedding of discharged patients with severe COVID-19. *Clinical Infectious Diseases* 2020; **17**: 17.
43. Sakurai A, Sasaki T, Kato S, et al. Natural History of Asymptomatic SARS-CoV-2 Infection. *New England Journal of Medicine* 2020.
44. Talmy T, Tsur A, Shabtay O. Duration of Viral Clearance in IDF Soldiers with Mild COVID-19. *medRxiv*.
45. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. *Clinical Infectious Diseases* 2020; **19**: 19.

46. Shastri A, Wheat J, Agrawal S, et al. Delayed clearance of SARS-CoV2 in male compared to female patients: High ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs.
47. Ling Y, Xu S-B, Lin Y-X, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chinese Medical Journal* 2020; **133**(9).
48. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Medical Journal of Australia* 2020; **212**(9): 416-20.
49. Liang M, Chen P, He M, et al. Corticosteroid Treatment in Critically Ill Patients with COVID-19: A Retrospective Cohort Study. *ResearchSquare* 2020.
50. Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *The Lancet* 2020; **395**(10238): 1695-704.
51. Huang H, Guan L, Yang Y, et al. Chloroquine, arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study. 2020.
52. Zhou R, Li F, Chen F, et al. Viral dynamics in asymptomatic patients with COVID-19. *International Journal of Infectious Diseases* 2020; **96**: 288-90.
53. Chau NVV, Thanh Lam V, Thanh Dung N, et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. *Clinical Infectious Diseases* 2020.
54. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *New England Journal of Medicine* 2020; **382**(22): 2081-90.
55. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences* 2020; **63**(5): 706-11.
56. Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. *JAMA Netw Open* 2020; **3**(5).
57. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clinical Infectious Diseases*.
58. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* 2020: 1-3.
59. Le TQM, Takemura T, Moi ML, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Shedding by Travelers, Vietnam, 2020. *Emerg Infect Dis* 2020; **26**(7): 02.
60. To KK-W, Tsang OT-Y, Yip CC-Y, et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. *Clinical Infectious Diseases* 2020; (c1aa149).
61. Liu W, Tang F, Fontanet A, et al. Long-term SARS coronavirus excretion from patient cohort, China. *Emerg Infect Dis* 2004; **10**(10): 1841-3.
62. Xiao F, Sun J, Xu Y, et al. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. *Emerging Infectious Disease journal* 2020; **26**(8).
63. Andersson M, Arancibia - Carcamo CV, Auckland K, et al. SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus. *medRxiv*.
64. Chan PK, To WK, Ng KC, et al. Laboratory diagnosis of SARS. *Emerg Infect Dis* 2004; **10**(5): 825-31.
65. Chen WJ, Yang JY, Lin JH, et al. Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms. *Clinical Infectious Diseases* 2006; **42**(11): 1561-9.
66. Xu D, Zhang Z, Jin L, et al. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. *European Journal of Clinical Microbiology and Infectious Diseases* 2005; **24**(3): 165-71.
67. Cheng PK, Wong DA, Tong LK, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. *Lancet* 2004; **363**(9422): 1699-700.
68. Kwan BC, Leung CB, Szeto CC, et al. Severe acute respiratory syndrome in dialysis patients. *J Am Soc Nephrol* 2004; **15**(7): 1883-8.

69. Leong HN, Chan KP, Khan AS, et al. Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital. *Emerg Infect Dis* 2004; **10**(10): 1745-50.
70. Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *The Lancet* 2003; **361**(9371): 1767-72.
71. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. *Sci* 2016; **6**: 25359.
72. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. *J Antimicrob Chemother* 2015; **70**(7): 2129-32.
73. Al Hosani FI, Pringle K, Al Mulla M, et al. Response to Emergence of Middle East Respiratory Syndrome Coronavirus, Abu Dhabi, United Arab Emirates, 2013-2014. *Emerg Infect Dis* 2016; **22**(7): 1162-8.
74. Oh MD, Park WB, Choe PG, et al. Viral load kinetics of MERS coronavirus infection. *New England Journal of Medicine* 2016; **375**(13): 1303-5.
75. Arabi YM, Al-Omari A, Mandourah Y, et al. Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. *Crit Care Med* 2017; **45**(10): 1683-95.
76. Hong KH, Choi JP, Hong SH, et al. Predictors of mortality in Middle East respiratory syndrome (MERS). *Thorax* 2018; **73**(3): 286-9.
77. Corman VM, Albarak AM, Omrani AS, et al. Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection. *Clinical Infectious Diseases* 2016; **62**(4): 477-83.
78. Muth D, Corman VM, Meyer B, et al. Infectious middle east respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia. *Journal of Clinical Microbiology* 2015; **53**(9): 2951-5.
79. Wang Y, Tian H, Zhang L, et al. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Global Health* 2020; **5**(5): e002794.
80. Böhmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *The Lancet Infectious Diseases*.
81. Cheng H-Y, Jian S-W, Liu D-P, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Internal Medicine* 2020.
82. Wang Y, Guo Q, Yan Z, et al. Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. *J Infect Dis* 2018; **217**(11): 1708-17.
83. Memish A. Viral shedding and antibody response in MERS. *Vox Sanguinis* 2016; **111** (Supplement 1): 48-9.
84. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* 2020; **323**(18): 1843-4.
85. Ip DKM, Lau LLH, Leung NHL, et al. Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community. *Clin Infect Dis* 2017; **64**(6): 736-42.
86. Walsh KA, Jordan K, Clyne B, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. *Journal of Infection*.
87. Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wijgert JHHM, Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. *The Lancet Public Health*.

88. Chang D, Mo G, Yuan X, et al. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. *Am J Respir Crit Care Med* 2020; **201**(9): 1150-2.
89. Chen X, Ling J, Mo P, et al. Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. *medRxiv* 2020: 2020.03.03.20030437.
90. Corman VM, Rabenau HF, Adams O, et al. SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission. *Transfusion* 2020; **60**(6): 1119-22.
91. Fu S, Fu X, Song Y, et al. Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan, China. 2020.
92. Huang L, Chen Z, Ni L, et al. Impact of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Inflammatory Responses and Viral Clearance in COVID-19 Patients: A Multicenter Retrospective Cohort Study. *ResearchSquare* 2020.
93. Li N, Wang X, Lv T. Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. *Journal of Medical Virology*; **n/a**(n/a).
94. Liu L, Liu W, Zheng Y, et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. *Microbes and Infection* 2020; **22**(4): 206-11.
95. Lo IL, Lio CF, Cheong HH, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. *Int J Biol Sci* 2020; **16**(10): 1698-707.
96. Lou B, Li T, Zheng S, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset.
97. Pongpirul WA, Mott JA, Woodring JV, et al. Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC.
98. Qian GQ, Chen XQ, Lv DF, et al. Duration of SARS-CoV-2 viral shedding during COVID-19 infection. *Infect Dis (Lond)* 2020: 1-2.
99. quan w, zheng q, tian j, et al. No SARS-CoV-2 in expressed prostatic secretion of patients with coronavirus disease 2019: a descriptive multicentre study in China.
100. Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients. *Ophthalmology* 2020; **24**: 24.
101. Song C, Wang Y, Li W, et al. Detection of 2019 novel coronavirus in semen and testicular biopsy specimen of COVID-19 patients.
102. Song R, Han B, Song M, et al. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. *Journal of Infection* 2020.
103. Tu Y-H, Wei Y-Y, Zhang D-W, Chen C-S, Hu X-W, Fei G. Analysis of factors affected the SARS-CoV-2 viral shedding time of COVID-19 patients in Anhui, China: a retrospective study. 2020.
104. Wang L, Gao Y-h, Lou L-L, Zhang G-J. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. *European Respiratory Journal* 2020.
105. Wang S, Tu J, Sheng Y. Clinical characteristics and fecal-oral transmission potential of patients with COVID-19. *medRxiv*.
106. Wu B, Lei Z-Y, Wu K-L, et al. Epidemiological and clinical features of imported and local patients with coronavirus disease 2019 (COVID-19) in Hainan, China. *ResearchSquare* 2020.
107. Xu I, Zhang X, Song W, et al. Conjunctival polymerase chain reaction-tests of 2019 novel coronavirus in patients in Shenyang, China.
108. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. 2020.
109. Xu D, Zhang Z, Jin L, et al. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. *Eur J Clin Microbiol Infect Dis* 2005; **24**(3): 165-71.
110. Al-Jasser FS, Nouh RM, Youssef RM. Epidemiology and predictors of survival of MERS-CoV infections in Riyadh region, 2014-2015. *J Infect Public Health* 2019; **12**(2): 171-7.

111. Alkendi F, Nair SC, Hashmey R. Descriptive Epidemiology, Clinical Characteristics and Outcomes for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infected Patients in AlAin - Abu Dhabi Emirate. *J Infect Public Health* 2019; **12 (1)**: 137.
112. Park WB, Poon LLM, Choi SJ, et al. Replicative virus shedding in the respiratory tract of patients with Middle East respiratory syndrome coronavirus infection. *International Journal of Infectious Diseases* 2018; **72**: 8-10.